Publikationsdatenbank

Core-Multishell-Nanocarriers, Potential Drug Transporters, have no Impact on Atopic Dermatitis or Psoriasis in Murine Models (2015)

Art

Vortrag

Autoren

Pischon, H.

Radbruch, M. (WE 12)

Ostrowski, A. (WE 12)

Unbehauen, M.

Haag, R.

Gruber, A. D. (WE 12)

Mundhenk, L. (WE 12)

Kongress

The 33rd Annual Meeting of The European Society of Veterinary Pathology & The 26th Annual Meeting of The European College of Veterinary Pathologists

Helsinki, Finnland, 02. – 05.09.2015

Quelle

Journal of Comparative Pathology; 154(1) — S. 73

ISSN: 0021-9975

Sprache

Englisch

Verweise

URL (Volltext): http://www.sciencedirect.com/science/article/pii/S0021997515001723

DOI: 10.1016/j.jcpa.2015.10.037

Kontakt

Institut für Tierpathologie

Robert-von-Ostertag-Str. 15
Gebäude 12
14163 Berlin
+49 30 838 62450

Abstract / Zusammenfassung

Introduction:
Atopic dermatitis and psoriasis are common inflammatory skin diseases, which cannot be treated effectively due to poor epidermal penetration (of drugs such as tacrolimus) and adverse side-effects after long-term treatment (with drugs such as dexamethasone). Core-multishell-nanocarriers (CMS-NCs) are innovative, biocompatible drug transporters, designed to enhance dermal drug uptake, concentrate drugs at the site of action and thereby minimize side-effects. The aim of this study was to investigate the impact of drug unloaded CMS-NCs on inflammatory skin diseases.

Materials and Methods:
Atopic dermatitis and psoriasis-like dermatitis were induced chemically in SKH1 or BALB/c mice, respectively. CMS-NCs or solvent were applied topically to inflamed skin or the skin of healthy controls twice daily for 5 consecutive days. The clinical course of the disease was assessed by monitoring the transepidermal water loss, erythema and water-holding capacity of the stratum corneum. Epidermal thickness and degree of inflammation were characterized histopathologically.

Results:
In both experimentally induced inflammatory skin diseases, no effects of CMS-NC were observed in any of the clinical and histological parameters studied.

Conclusions:
Unlike other nanoparticles, unloaded CMS-NCs do not modulate atopic dermatitis and psoriasis-like dermatitis in mice. This underlines their biocompatibility and suggests that CMS-NCs may be used for drug transportation in inflammatory skin diseases.